In this regard, patients affected by IDH-mutated poorly differentiated and undifferentiated sinonasal carcinomas could benefit from specific treatments with mutant IDH inhibitors [114], while SWI/SNF-deficient carcinomas could be targeted by inhibitors of EZH2 [115,116]. This evidence concerns the gene IDH2 and nasal cavity and paranasal sinus carcinoma.